ArticleCureus2025
Bullous Pemphigoid Secondary to Dipeptidyl Peptidase-4 (DPP4) Inhibitor: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous pemphigoid (BP) is a rare acquired subepidermal autoimmune disease characterized by the presence of blisters on the skin. Recently, a possible association has been reported between the use of DPP-4 inhibitors, an oral antidiabetic, and an increased risk of BP. The mechanisms underlying this increased risk remain poorly understood. We present the case of an 80-year-old diabetic man who developed scattered blistering pruritic lesions on the trunk and limbs, which had been progressively worsening over approximately 6 months and difficult to resolve. After investigating his medical history and observing significant improvement following the administration of topical corticosteroids, the clinical presentation was associated with the use of a DPP-4 inhibitor. In conclusion, the case presented suggests a cause-and-effect relationship between BP and DPP-4 inhibitors. Early recognition of these adverse reactions is crucial to establish appropriate interventions to prevent the progression of conditions such as BP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.